These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9225136)

  • 41. Intranasal complications in women with osteoporosis under treatment with nasal calcitonin spray: case reports and review of the literature.
    Chatziavramidis A; Mantsopoulos K; Gennadiou D; Sidiras T
    Auris Nasus Larynx; 2008 Sep; 35(3):417-22. PubMed ID: 18053666
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Comparison of calcitonin tolerance after intramuscular or intranasal administration in treatment for postmenopausal osteoporosis].
    Horst-Sikorska W; Ruszkowska J; Kosowicz J
    Przegl Lek; 1996; 53(1):9-11. PubMed ID: 8711177
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and tolerability of calcitonin in the prevention and treatment of osteoporosis.
    Halkin V; Reginster JY
    BioDrugs; 1998 Oct; 10(4):295-300. PubMed ID: 18020602
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.
    Reginster JY; Denis D; Deroisy R; Lecart MP; De Longueville M; Zegels B; Sarlet N; Noirfalisse P; Franchimont P
    J Bone Miner Res; 1994 Jan; 9(1):69-73. PubMed ID: 8154311
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
    Holloway L; Kohlmeier L; Kent K; Marcus R
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Using miacalcic nasal spray 200 UI in the treatment of osteoporosis in women of 40-70 years of age during menopause according to data of the center "Osteoporosis" in Khaskovo city].
    Staĭkova N; Filipov P
    Akush Ginekol (Sofiia); 2004; 43 Suppl 1():10-4. PubMed ID: 15323311
    [No Abstract]   [Full Text] [Related]  

  • 47. [Calcitonin in the prevention and therapy of osteoporosis].
    Ringe JD
    Ther Umsch; 1991 Feb; 48(2):91-9. PubMed ID: 2035172
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of postmenopausal osteoporosis with salmon calcitonin nasal spray: evaluation by bone mineral content and biochemical patterns.
    Tolino A; Romano L; Ronsini S; Riccio S; Montemagno U
    Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):358-60. PubMed ID: 8370634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analgesic efficacy of calcitonin for vertebral fracture pain.
    Blau LA; Hoehns JD
    Ann Pharmacother; 2003 Apr; 37(4):564-70. PubMed ID: 12659616
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Salmon calcitonin in the treatment of osteoporosis].
    Payer J; Killinger Z; Ondrejka P
    Vnitr Lek; 1999 Aug; 45(8):476-9. PubMed ID: 11045148
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients.
    Hesch RD; Busch U; Prokop M; Delling G; Rittinghaus EF
    Calcif Tissue Int; 1989 Mar; 44(3):176-80. PubMed ID: 2493323
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Calcitonin and bone aging].
    Reginster JY
    Pathol Biol (Paris); 1997 Jan; 45(1):52-6. PubMed ID: 9097847
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Calcitonins and osteoporosis.
    Gennari C; Agnusdei D
    Br J Clin Pract; 1994; 48(4):196-200. PubMed ID: 7917799
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Calcitonins: newer routes of delivery.
    Reginster JY
    Osteoporos Int; 1993; 3 Suppl 2():S3-6; discussion S6-7. PubMed ID: 8481597
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
    Tankó LB; Bagger YZ; Alexandersen P; Devogelaer JP; Reginster JY; Chick R; Olson M; Benmammar H; Mindeholm L; Azria M; Christiansen C
    J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Comparison of the effectiveness of 17-beta-estradiol and calcitonin in women with postmenopausal bone loss].
    Stĕpán J; Formánková J; Masatová A; Michalský M; Rosenová Z
    Cas Lek Cesk; 1997 Apr; 136(8):242-8. PubMed ID: 9264868
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of calcitonin in the prevention of osteoporosis.
    Avioli LV
    Endocrinol Metab Clin North Am; 1998 Jun; 27(2):411-8. PubMed ID: 9669146
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomised placebo-controlled trial on the effectiveness of nasal salmon calcitonin in the treatment of lumbar spinal stenosis.
    Tafazal SI; Ng L; Sell P
    Eur Spine J; 2007 Feb; 16(2):207-12. PubMed ID: 16865379
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.
    Civitelli R; Gonnelli S; Zacchei F; Bigazzi S; Vattimo A; Avioli LV; Gennari C
    J Clin Invest; 1988 Oct; 82(4):1268-74. PubMed ID: 3262626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.